| Patient | Howard Hughes |
|---|---|
| Date of birth | 1984-12-24 |
| Identifiers | MRN HR-ML006-SYN; SSN (made up) 000-06-5571 |
| Document date | 2026-10-05 |
| Author | Anselm Garrity-Moyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twenty-two-week review: OCD response, buprenorphine, pain, weight and laboratory checks. [S]
Mr. Hughes returns three weeks after his preventive visit and twelve weeks after the increase to sertraline 200 mg, which he tolerates with mild night sweats; the nurse call two weeks after the increase found no problems. He has had twenty exposure sessions. He eats in a restaurant once a week, holds meetings without asking visitors about illness, and no longer needs sealed milk bottles. Washing and checking take about one hour a day, and he says the fears are now "background noise." He has used no opioid other than buprenorphine; the urine test today was positive for buprenorphine and negative for other opioids and fentanyl. He wears his hearing aids every day and uses the remote microphone in meetings. He would like his COVID-19 vaccine today. [S]
| Element | Detail |
|---|---|
| Rituals | About one hour a day; Y-BOCS 14 |
| Sertraline | 200 mg for twelve weeks; mild night sweats |
| Buprenorphine | 8 mg twice daily; urine test as expected |
| Pain | PEG 4.0 |
| Weight | 76.2 kg, up 4.2 kg since intake |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight up |
| Gastrointestinal | Negative | Bowels regular |
| Musculoskeletal | Positive | Mild chest wall and back pain on long days |
| Psychiatric | Negative | Contamination fears mild; mood good; no thoughts of suicide or of harming anyone |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 300 mg with codeine 30 mg oral tablet, prescribed elsewhere since the crash as one or two tablets every 6 hours as needed, no more than 8 a day; he has been taking 10 to 12 a day | One or two tablets every 6 hours as needed, no more than 8 a day | Oral route | 2026-05-04 to 2026-05-11 | completed | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff | One spray as needed for suspected overdose; repeat in 2 to 3 minutes if needed | Nasal route | 2026-05-04 | active | S |
| Buprenorphine 2 mg with naloxone 0.5 mg sublingual film for the first day: 4 mg once withdrawal is moderate (COWS 12 or more), then 2 to 4 mg every one to two hours as needed, to no more than 16 mg on the first day | First-day induction by the written plan, no more than 16 mg | Sublingual route | 2026-05-11 to 2026-05-12 | completed | S |
| Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at first | One film under the tongue twice daily | Sublingual route | 2026-05-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped | Two tablets three times daily, no more than 3,000 mg a day | Oral route | 2026-05-11 | active | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-05-11 to 2026-06-08 | completed | S |
| Sertraline 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-08 to 2026-07-13 | completed | S |
| Sertraline 100 mg oral tablet, two tablets daily (200 mg), the usual target range for OCD | Two tablets daily | Oral route | 2026-07-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-05 | Body height | 191 | cm | S |
| 2026-10-05 | Body weight | 76.2 | kg | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 20.9 | kg/m2 | S |
| 2026-10-05 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-05 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-05 | Heart rate | 72 | /min | S |
| 2026-10-05 | Respiratory rate | 14 | /min | S |
| 2026-10-05 | Body temperature | 36.6 | Cel | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-05 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-05 | Glucose [Mass/volume] in Serum or Plasma | 86 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-40 U/L | Normal | S |
| 2026-10-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-56 U/L | Normal | S |
| 2026-10-05 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-10-05 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-10-05 | Mean score [PEG] | 4 | {score} | S |
Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 72; weight 76.2 kg, BMI 20.9 |
| Skin | Hands healed |
| Musculoskeletal | Full left shoulder elevation; mild tenderness of the left lower ribs |
| Psychiatric | Relaxed and humorous; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Intrusive fears of contamination by germs for about a year, worse since the crash, with hand washing, cleaning of objects and avoidance of handshakes, shared spaces and food handled by others, taking about four hours a day; he recognizes the fears are probably excessive; cause under evaluation | resolved | confirmed | R46.81 | S — Synthetic presenting problem anchored to his documented fear of germs; resolved into the diagnosis of OCD at the consultation. Not a claim about his real symptoms in 1947. |
| Obsessive-compulsive disorder, contamination type, with good or fair insight, not tic-related; Y-BOCS 28 (severe) at intake; no post-traumatic stress disorder on screening | active | confirmed | F42.2 | S — Synthetic modern diagnosis made at the consultation, linked to the retrospective interpretation of his documented fears (R). Not a claim about his real diagnosis. |
| Opioid use disorder, moderate (four of the DSM-5-TR criteria that count for a prescribed opioid: taking more than prescribed, failed attempts to cut down, time spent getting prescriptions from two prescribers, and craving), on codeine prescribed after a crash; buprenorphine planned | active | confirmed | F11.20 | S — Synthetic modern coding; tolerance and withdrawal are not counted for a medicine taken under medical supervision. Person-first language; not a claim about his real diagnosis. |
| Chronic pain after major trauma ten months ago (crushed chest with rib fractures, collapsed lung, other fractures and burns): chest wall, left shoulder and low back pain, PEG 6.7 | active | confirmed | G89.21 | S — Synthetic modern diagnosis anchored to his documented injuries. |
| Difficulty hearing conversation, worse in noise, after years of flying in loud aircraft; cause under evaluation | resolved | confirmed | H91.93 | S — Synthetic presenting problem; resolved into a diagnosis when audiometry was done at five weeks. His documented deafness is from later years. |
| Bilateral high-frequency sensorineural hearing loss with a notch at 4000 Hz, consistent with noise exposure from flying; hearing aids fitted | active | confirmed | H90.3 | S — Synthetic modern diagnosis made at five weeks; not a claim about his real hearing in 1947. |
| Weight loss of about 8 kg since the crash (BMI 19.7), from eating little outside food he has prepared or inspected himself because of contamination fears | active | confirmed | R63.4 | S — Synthetic nutrition problem linked to the contamination fears; not a claim about his real weight in 1947. |
| Acute bronchitis, likely viral, for five days; no pneumonia on examination; resolved within three weeks without antibiotics | resolved | confirmed | J20.9 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | OCD severity (Y-BOCS, clinician-rated) and time spent on rituals | Every visit | Completed today | Y-BOCS 14, a 50 percent fall; about one hour a day |
| Referral | Exposure and response prevention: sessions attended and home practice | Weekly, then twice weekly | Completed today | Twenty sessions attended; moving to weekly, then booster sessions |
| Medication safety | SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughts | Every visit, and two weeks after each start or dose change | Completed today | Nurse call after the increase done; mild night sweats; sodium 140 mmol/L |
| Self-management | Accommodation by staff, reduced step by step with his consent | Every visit | Completed today | No rituals carried out by staff apart from his own choice of sealed water bottles at the factory |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and at least monthly during acute treatment | Completed today | PHQ-9 4, item 9 scored 0; GAD-7 6 |
| Survey | Suicide risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone; 988 in his phone |
| Self-management | Opioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation) | Every visit | Completed today | No cravings and no other opioid use |
| Laboratory | Urine drug test with fentanyl and buprenorphine, with consent | At start, then about monthly in the first months | Completed today | Positive for buprenorphine, negative for fentanyl and other opioids |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's buprenorphine |
| Medication safety | Naloxone at home and household staff trained | Every visit | Completed today | Naloxone at home |
| Survey | Pain intensity and interference (PEG) and function | Every visit | Completed today | PEG 4.0 |
| Examination | Weight, meals and nutrition | Every visit | Completed today | 76.2 kg, BMI 20.9; albumin 4.2 g/dL |
| Laboratory | Kidney function, liver enzymes and albumin | At baseline and at about six months on scheduled acetaminophen | Completed today | Potassium 4.3 mmol/L, creatinine 0.96 mg/dL, eGFR 102, glucose 86 mg/dL, AST 24, ALT 27 |
| Imaging | Hearing: audiometry, hearing aids and use | Audiometry once; hearing aid review after fitting | Completed today | Audiologist review last month; hearing aids worn daily |
Goal progress:
Immunizations given today: COVID-19 vaccine for the coming season [S]
Guideline basis: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Prescription Drug Monitoring Programs (PDMPs) (2026); Hearing loss in adults: assessment and management (NG98) (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Adult Immunization Schedule by Age (2026)
Follow-up: COVID-19 vaccine given today. Second hepatitis B dose next week. Review in three months. Call the clinic or 988 at any time. [S]